Show simple item record

dc.creatorRadosavljevic, V
dc.creatorRistovski, K
dc.creatorObradovic, Z
dc.date.accessioned2020-12-09T20:45:55Z
dc.date.available2020-12-09T20:45:55Z
dc.date.issued2013-11-25
dc.identifier.issn1755-8794
dc.identifier.issn1755-8794
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/4182
dc.identifier.other24565439 (pubmed)
dc.identifier.urihttp://hdl.handle.net/20.500.12613/4200
dc.description.abstractAcute inflammation is a severe medical condition defined as an inflammatory response of the body to an infection. Its rapid progression requires quick and accurate decisions from clinicians. Inadequate and delayed decisions makes acute inflammation the 10th leading cause of death overall in United States with the estimated cost of treatment about $17 billion annually. However, despite the need, there are limited number of methods that could assist clinicians to determine optimal therapies for acute inflammation. We developed a data-driven method for suggesting optimal therapy by using machine learning model that is learned on historical patients' behaviors. To reduce both the risk of failure and the expense for clinical trials, our method is evaluated on a virtual patients generated by a mathematical model that emulates inflammatory response. In conducted experiments, acute inflammation was handled with two complimentary pro- and anti-inflammatory medications which adequate timing and doses are crucial for the successful outcome. Our experiments show that the dosage regimen assigned with our data-driven method significantly improves the percentage of healthy patients when compared to results by other methods used in clinical practice and found in literature. Our method saved 88% of patients that would otherwise die within a week, while the best method found in literature saved only 73% of patients. At the same time, our method used lower doses of medications than alternatives. In addition, our method achieved better results than alternatives when only incomplete or noisy measurements were available over time as well as it was less affected by therapy delay. The presented results provide strong evidence that models from the artificial intelligence community have a potential for development of personalized treatment strategies for acute inflammation. © 2013 Radosavljevic et al; licensee BioMed Central Ltd.
dc.format.extentS7-S7
dc.language.isoen
dc.relation.haspartBMC Medical Genomics
dc.relation.isreferencedbySpringer Science and Business Media LLC
dc.rightsPublic Domain
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/
dc.subjectAcute Disease
dc.subjectAlgorithms
dc.subjectAnti-Inflammatory Agents
dc.subjectArtificial Intelligence
dc.subjectComputer Simulation
dc.subjectDose-Response Relationship, Drug
dc.subjectHumans
dc.subjectInflammation
dc.subjectModels, Biological
dc.subjectOutcome Assessment, Health Care
dc.titleA data-driven acute inflammation therapy
dc.typeArticle
dc.type.genreJournal Article
dc.relation.doi10.1186/1755-8794-6-S3-S7
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.date.updated2020-12-09T20:45:51Z
refterms.dateFOA2020-12-09T20:45:55Z


Files in this item

Thumbnail
Name:
A data-driven acute inflammation ...
Size:
836.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Public Domain
Except where otherwise noted, this item's license is described as Public Domain